CSL Seqirus Expands U.S. Flu Vaccine Supply After Early Campaign Completion

CSL Seqirus expanded U.S. influenza vaccine availability after completing its 2026/27 manufacturing campaign ahead of schedule, with most orders shipped and extra doses on hand amid broader market supply challenges.Material DetailsContext by AI AnalystThis is a mid-cycle operational update signalin…